New FDA Approved Drugs
Posted: Jan 06 2017
Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.

New Brand Approvals
Drug NameUses/TreatmentPricing InformationOther Information
Synjardy XR (empagliflozin/metformin)Treatment of type 2 diabetes as an adjunct to diet and exercisePricing information not yet available• Drug Information: Synjardy XR is a once-daily combination of empagliflozin (a SGLT2 inhibitor) and metformin (a biguanide).
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• Diabetes CareTrakRXTM: Synjardy XR will be added to the formulary alignment component of the Diabetes Management Program.
Rubraca (rucaparib)Treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer$8,244 monthly (AWP)• Drug Information: Rubraca is indicated as monotherapy for patients who have been previously treated with two or more chemotherapies.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak’s BIC Specialty Pharmacy Network. 
Spinraza (nusinersen)Treatment of spinal muscular atrophy (SMA)in pediatric and adult patients*$900,000 (AWP) for first year of treatment
*$450,000 (AWP) annually thereafter
• Drug Information: Spinraza is the first medication approved by the FDA for the treatment of spinal muscular atrophy.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to Max Dollar and Max Dose edits.
• Clinical Concierge: Spinraza will be subject to MedTrak’s 90 day new drug review process.  This process involves a comprehensive review of the medical literature and data surrounding this medication product.


The Clinical Care Center (CCC) is MedTrak’s comprehensive clinical solution to control costs and increase adherence for our Clients and Members. The Clinical Care Center is made up of 7 Steps to Improved Outcomes: Generics Plus, Formulary Management, Member & Client Education, RightChoice, Control Trak, Best-In-Class (BIC) SpecialtyRx, and Clinical Concierge.